only for those that already knew this information, for a newbie it is a great starting place for dd.
Yes, they spent money on infrastructure and ha dto keep their own help desk and contracted help desk working together. They needed it and rather than pay taxes spend the money on something you needs is very smart.
This is not about nickels and dimes know it is about a growing product line with major partnerships.
Look beyond 6 months.
With only a few posts ever and all shameless basher posts, if you want to add credibility tell us about your self.
Credentials, education, history of this industry and stock and stocks you are long as well as your other id's.
Take your time answer by Monday am is okay.
This does not add up, with 91% of the shares owned by institutions and insiders along with retail longs owning say 10% how do shorts ever expect to cover?
They are now short almost 10 million shares. MElissa and Tigress Financial better start writing now.
This is going to move like a huge tsunami when ebix announces new buyback, oh to be a fly on the large shorts wall when this happens.
Remember growing fcf, sales, eps, market share, long term contracts the story just keeps getting better.
Thanks, I always thought luxury will hit a ceiling while demand will be stronger on middle tier apts.
As more people wait until they buy a home we will see millennials renting for a lot longer than boomers.
Locally, Boston condo's are outta sight in terms of prices and as a result rents in the 128 belt are up sharlply as more people need to commute as they cannot afford the inner city to either buy or rent.
FYI : 2 br in Boston is fast approaching and avg of 3k + utilities. Does not include parking either.
Waterfront , Beacon Hill and Back Bay are 3k - 5k for 2br.
Weeeeeee, still bashing living under a bridge and collecting welfare, way to go.
Good mngt will find many ways to increase cash flow and grow a company.
The MJFF grant is expected to fully fund a preclinical study on the effect of ANAVEX 2-73 in a Parkinson’s disease animal model, which seeks to provide a solid dataset that will justify moving forward to clinical development in Parkinson’s. The study may also provide further evidence for the involvement of sigma-1 receptors in potentially disease-modifying therapies for Parkinson’s disease.
As a potential platform drug and the Company’s lead therapeutic, ANAVEX 2-73 targets misfolded proteins central to many neurodegenerative diseases, including Parkinson’s and Alzheimer’s. It is believed to enhance the body's own cellular defense mechanisms through both sigma-1 and muscarinic receptors to return diseased cells to a pre-diseased or “homeostatic” state.
“The development of disease-modifying therapies for Parkinson’s disease is the top priority of The Michael J. Fox Foundation and ANAVEX 2-73 presents a promising approach,” said Marco Baptista, PhD, Senior Associate Director of MJFF Research Programs. “Companies that receive funding from MJFF have scientifically compelling plans that hold obvious potential to impact our understanding of Parkinson’s and ultimately the development of improved treatments for people with the disease. To that end, we look forward to the results of the ANAVEX 2-73 study.”
“If successful, this study will accelerate the translation of preclinical findings into the very first clinical trial of ANAVEX 2-73 as a potential disease-modifying therapy for Parkinson’s disease,” said Angela Cenci, MD, PhD, and Professor at Lund University, where the study will be conducted. “We are in the fortunate position that ANAVEX 2-73 has already been tested for safety and tolerability in humans, and was found to be a good clinical drug candidate.”
“Anavex is honored to have The Michael J. Fox Foundation for Parkinson’s Research support the development of our technology and we are pleased to be collaborating with such a prestigious organization,” said C
first its diabetes, next they will go after the pain and oncology market with their tech...
Who buys them first?
he needs some lube
I just love it when I am up over 100% and dummarrrzez like you come on the board and think you have a clue. You create about 45 fake id's have no money play games and maybe have a ged.
You guys ar eliars, always selling or shorting the top and coverign the bottom, if you guys did what you say you did you would al be running hedge funds instead of playing make believe with your bs warstories and circle jerks.
Lots of drama here as the shorts attacked with everything they had. Stories form StreetSweeper Citron and independent's all bashing with more fake stories such as irs, fraud, sec, dept of justice lies blah blah.
Every story was bs, and over the last 6 months they purchase d two co's increased earnings big time, got a large activist investor, had the IRS sign off on a deep audit with few changes, won major contracts and all shorts are now trapped and underwater big time.
So here we sit a double this year and over 20% float short and trapped.
EBIX will increase earnings and cash flow, do lots of buybacks buy more co's and move slowly to mid 50's all without short covering add in short covering and who knows.
I added 500 more shares on this latest dip.
Accenture is one of the largest IT consulting co's in the world..
They created the software to interact with the Vuzi glasses os which will be replicated in hundreds of other concepts.
They key is that software developers actually write software to make the glasses work.
So much new on Vuzi so much opportunity, if Fitbit is 7.8 billion then 1 billion for Vuzi is not far off.
They will be bought out within 2 years that is a given.
I see more practible application and uses for smart glasses than a fitbit just taking my temp and heartbeat.
Would love to have a ticker scrolling on the bottom of my smartglass RayBans on the beach, scanttilly clad babes, stock market and rum,,, OH Yeah.......
I own VUZI, EMAN and KOPN.
Up up and away.
There are a lot of co's flying under the radar and if they ipo'd they would trade at 2 to 3 times the current price.
Agree with you 100%
OZARK pretty much said this could happen and knowing that the shorts will do anything to dorp this, I sold 2/3 and added back on the big dip missed the bottom but still got in at -1.57.
Shorts still have a long way to cover..
One thing they forgot was the longs that do remain know the story very well and that it will be very hard to shake shares free. In a crazy market ebix is pretty safe.